Fusion Antibodies (FAB.L) Stock Price

£13.25 0%

Sign up
to add to portfolio

AI Score

Hold

  • Alternative

    7

  • Fundamental

    8

  • Technical

    7

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Fusion Antibodies, AI stock picks, stock alerts and much more.

Sign up

FAB.L AI Stock Analysis

AI stock analysis for FAB.L is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Fusion Antibodies (FAB.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Fusion Antibodies (FAB.L) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Fusion Antibodies (FAB.L), currently trading at £13.25, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About FAB.L

LSE

  • Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally.

  • Symbol

    FAB.L

  • Market

    LSE

  • Industry

    Biotechnology

  • Market Cap

    15.1M

Similar Stocks

0I0X.L Codexis
0I0X.L		 $3
5.5%
5
ONT.L Oxford Nanopore Technologies plc
ONT.L		 £208.2
1.3%
7
SAR.L Sareum Holdings
SAR.L		 £22
8.3%
5
0K1R.L Viridian Therapeutics
0K1R.L		 $19.19
8.5%
6
AVCT.L Avacta Group Plc
AVCT.L		 £49
1%
4

News

Augurex Announces UKCA Authorization for SPINEstat™, Expanding Access to a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis to Great Britain

Augurex Announces UKCA Authorization for SPINEstat™, Expanding Access to a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis to Great Britain
April 22, 2025. Financial Post
Purging viral latency by a bifunctional HSV-vectored therapeutic vaccine in chronically SIV-infected macaques

Purging viral latency by a bifunctional HSV-vectored therapeutic vaccine in chronically SIV-infected macaques
April 22, 2025. Elifesciences.org
Augurex Secures Health Canada Approval for SPINEstat™, a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis

Augurex Secures Health Canada Approval for SPINEstat™, a First-in-Class Diagnostic Blood Test for Axial Spondyloarthritis
April 16, 2025. Financial Post
Viruses of parasites: A roadmap toward diagnostic and therapeutic development

Viruses of parasites: A roadmap toward diagnostic and therapeutic development
April 10, 2025. Plos.org

FAB.L Alternative Data

Web Traffic

Fusion Antibodies receives an estimated 2915 monthly visitors to fusionantibodies.com.

  • Web Traffic

    2915

  • Change from Previous Month

    85.7%

  • 3 Month Change

    152.6%

  • YoY Change

    152.6%

Twitter Followers

Fusion Antibodies has 1,216 Twitter Followers on its main Twitter (also known as X) account, which is up by 0.7% over the last month.

  • Twitter Followers

    1216

  • Daily Change

    0%

  • 1 Month Change

    0.7%

  • 3 Month Change

    0.4%

  • YoY Change

    0.4%

Facebook Engagement

Fusion Antibodies has engaged 0 users via their Facebook Page over the last 7 days.

  • Facebook Engagement

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Job Postings

Fusion Antibodies currenly has an estimated 0 open job postings.

  • Job Postings

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

LinkedIn Followers

5,378 are following Fusion Antibodies on LinkedIn, up by 1.5% over the last month.

  • LinkedIn Followers

    5378

  • Daily Change

    1.5%

  • 1 Month Change

    1.5%

  • 3 Month Change

    3.7%

  • YoY Change

    3.7%

LinkedIn Employees

According to LinkedIn, Fusion Antibodies has 28 employees.

  • LinkedIn Employees

    28

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

Business Outlook

According to employee reviews, the business outlook among employees at Fusion Antibodies is 60 out of 100 (neutral).

  • Business Outlook

    60

  • Change from Previous Month

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

News Mentions

Fusion Antibodies was mentioned 4 times in the news yesterday.

  • News Mentions

    4

  • Daily Change

    100%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

Reddit Mentions

Fusion Antibodies has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • 1 Month Change

    0%

  • 3 Month Change

    0%

FAB.L Financials

FAB.L Key Metrics

  • Total Revenue

    £1.2M

  • Net Income

    -£758K

  • Earnings per Share

    -£0.0079

  • Free cash flow

    -£752K

  • EBITDA

    -£736K

  • EBITDA Ratio

    -0.609776

  • Total Assets

    £1.5M

FAB.L 2-year Revenue & Income
FAB.L 2-year Free Cash Flow

FAB.L Technicals

FAB.L SMA
FAB.L RSI

FAQ

What's the current price of Fusion Antibodies (FAB.L) Stock?
The price of an Fusion Antibodies (FAB.L) share is £13.25.

What's the market cap of Fusion Antibodies?
The current market cap of Fusion Antibodies is 15.1M.

Should I buy or sell FAB.L?
Multiple alternative data signals suggest that Fusion Antibodies stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.

Is Fusion Antibodies a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Fusion Antibodies stock. The bullish indicators suggest that Fusion Antibodies' growth prospects and market position may lead to a positive performance in the foreseeable future.

Is now a good time to buy Fusion Antibodies (FAB.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Fusion Antibodies stock, given the bullish outlook.

What are some stocks similar to Fusion Antibodies (FAB.L) that investors often compare it to?
Fusion Antibodies (FAB.L) is often compared to similar stocks such as Codexis, Oxford Nanopore Technologies plc, Sareum Holdings, Viridian Therapeutics and Avacta Group Plc.

What is the forecast for Fusion Antibodies' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Fusion Antibodies' stock price to be around £14.24 in 2026. Starting from the current price of £13.25, this represents a 7.5% change in price, indicating a bullish outlook for the stock.

How to buy Fusion Antibodies (FAB.L) Stock?
Fusion Antibodies stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Fusion Antibodies shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.